| Literature DB >> 25329153 |
Mengling Tang1, Kun Chen2, Fangxing Yang1, Weiping Liu1.
Abstract
OBJECTIVE: Though exposure to organochlorine pollutants (OCPs) is considered a risk factor for type 2 diabetes (T2DM), epidemiological evidence for the association remains controversial. A systematic review and meta-analysis was applied to quantitatively evaluate the association between exposure to OCPs and incidence of T2DM and pool the inconsistent evidence. DESIGN AND METHODS: Publications in English were searched in MEDLINE and WEB OF SCIENCE databases and related reference lists up to August 2013. Quantitative estimates and information regarding study characteristics were extracted from 23 original studies. Quality assessments of external validity, bias, exposure measurement and confounding were performed, and subgroup analyses were conducted to examine the heterogeneity sources.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25329153 PMCID: PMC4198076 DOI: 10.1371/journal.pone.0085556
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1The study search and selection process.
Study characteristics.
| Reference | Country | Study design | age | Exposure pathway | biomarker | Biologic specimen | Cases/controls | OR or RR (95%CI) |
| Arrebola2013 | Spain | Cross-sectional | 16- | Background |
| Serum lipid | 34/352 | 1.69(0.54–5.22) |
| Wu2012 | USA | Prospective | 30–55 | Nurses | PCB-153 | Serum lipid | 10/214 | 2.19(0.72–6.68) |
| 30–55 | Nurses | PCB-153 | Serum lipid | 6/135 | 0.76(0.22–2.60) | |||
| 30–55 | Nurses | PCBs | Serum lipid | 9/215 | 1.30(0.43–3.93) | |||
| 30–55 | Nurses | PCBs | Serum lipid | 7/134 | 0.79(0.23–2.71) | |||
| 30–55 | Nurses |
| Serum lipid | 9/215 | 1.32(0.41–4.27) | |||
| 30–55 | Nurses |
| Serum lipid | 10/131 | 1.79(0.54–5.86) | |||
| Persky2012 | USA | Cross-sectional | 35- | Electrical utilities company men | PCB-153 | Serum lipid | 7/56 | 3.1(1.2–7.8) |
| 35- | Electrical utilities company men | PCBs | Serum lipid | 7/56 | 3.0(1.3–7.2) | |||
| Gasull2012 | Spain | Cross-sectional | 18–74 | Background | PCB-153 | Serum | 77/192 | 1.6(1.2–2.4) |
| 18–74 | Background | PCBs | Serum | 77/193 | 1.7(1.1–2.6) | |||
| 18–74 | Background |
| Serum | 73/207 | 1.1(0.7–1.7) | |||
| Silverstone2012 | USA | Cross-sectional | 18- | PCBs plant area | PCBs | Serum | 78/157 | 2.78(1.00–7.73) |
| 18–55 | PCBs plant area | PCBs | Serum | 27/111 | 4.78(1.11–20.6) | |||
| 55- | PCBs plant area | PCBs | Serum | 51/47 | 4.19(0.26–68.12) | |||
| Lee 2011 | Sweden | Prospective | 70 | background | PCB-153 | Serum | 12/277 | 1.7(0.5–6.2) |
| 70 | background |
| Serum | 16/271 | 2.1(0.7–6.3) | |||
| Airaksinen2011 | Finland | Cross-sectional | 70 | background | PCB-153 | Serum lipid | 69/398 | 1.64(0.92–2.93) |
| 70 | background | PCB-153 | Serum lipid | 10/121 | 1.03(0.25–4.18) | |||
| 70 | background | PCB-153 | Serum lipid | 23/184 | 1.97(0.75–5.23) | |||
| 70 | background | PCB-153 | Serum lipid | 36/93 | 2.3(0.87–6.11) | |||
| 70 | background |
| Serum lipid | 62/398 | 1.75(0.96–3.19) | |||
| 70 | background |
| Serum lipid | 7/120 | 0.88(0.18–4.35) | |||
| 70 | background |
| Serum lipid | 18/175 | 1.91(0.69–5.27) | |||
| 70 | background |
| Serum lipid | 37/103 | 1.82(0.71–4.65) | |||
| Tanaka 2011 | Japan | Cross-sectional | 40–64 | background | PCB-153 | Serum | 32/85 | 0.95(0.90–1.00) |
| 40–64 | background | PCB-153 | Serum lipid | 32/85 | 0.73(0.51–1.07) | |||
| Grandjean2011 | Faroe Islands | Cross-sectional | 70–74 | Aquatic product | PCBs | Serum lipid | 168/544 | 1.11(0.91–1.35) |
| 70–74 | Aquatic product |
| Serum lipid | 168/544 | 1.01(0.87–1.16) | |||
| Son2010 | Korea | Cross-sectional | 40- | Background |
| Serum | 27/26 | 26.6(2.0–349.1) |
| 40- | Background |
| Serum lipid | 28/26 | 12.7(1.9–83.7) | |||
| Everett2010 | USA | Cross-sectional | 20- | Background |
| Serum lipid | 334/2715 | 1.08(0.58–2.03) |
| Ukropec2010 | Slovakia | Cross-sectional | 21–75 | Heavy pollution | PCBs | Serum lipid | 120/699 | 1.86(1.09–3.17) |
| 21–75 | Heavy pollution |
| Serum lipid | 125/694 | 1.94(1.11–3.78) | |||
| Lee2010 | USA | Perspective | 18–30 | Background | PCB-153 | Serum lipid | 39/45 | 0.8(0.2–2.6) |
| 18–30 | Background |
| Serum lipid | 47/45 | 0.7(0.2–1.9) | |||
| Philibert2009 | Canada | Cross-sectional | 15–86 | Aquatic product | PCB-153 | Serum | 25/101 | 4.91(1.27–19.01) |
| 15–86 | Aquatic product | PCB-153 | Serum lipid | 25/101 | 6.46(2.07–36.63) | |||
| 15–86 | Aquatic product | PCBs | Serum | 25/101 | 4.91(1.27–19.01) | |||
| 15–86 | Aquatic product | PCBs | Serum lipid | 25/101 | 5.51(1.26–24.07) | |||
| 15–86 | Aquatic product |
| Serum | 25/101 | 6.11(1.37–27.3) | |||
| 15–86 | Aquatic product |
| Serum lipid | 25/101 | 3.56(0.97–13.08) | |||
| Rignell-Hydbom2009 | Sweden | Prospective | 50–59 | Background women | PCB-153 | Serum | 371/371 | 0.99(0.71–1.4) |
| 50–59 | Background women | PCB-153 | Serum | 208/208 | 0.91(0.59–1.4) | |||
| 50–59 | Background women | PCB-153 | Serum | 163/163 | 1.1(0.66–1.9) | |||
| 50–59 | Background women | PCB-153 | Serum | 107/107 | 1.4(0.72–2.6) | |||
| 50–59 | Background women | PCB-153 | Serum | 74/74 | 1.4(0.67–3.1) | |||
| 50–59 | Background women | PCB-153 | Serum | 39/39 | 1.6(0.61–4.0) | |||
| 50–59 | Background women |
| Serum | 371/371 | 1.1(0.76–1.5) | |||
| 50–59 | Background women |
| Serum | 208/208 | 0.9(0.57–1.4) | |||
| 50–59 | Background women |
| Serum | 163/163 | 1.3(0.78–2.2) | |||
| 50–59 | Background women |
| Serum | 107/107 | 1.5(0.8–2.8) | |||
| 50–59 | Background women |
| Serum | 74/74 | 2.5(0.97–6.4) | |||
| 50–59 | Background women |
| Serum | 39/39 | 5.5(1.2–25) | |||
| Turyk2009 | USA | Prospective | 25–76 | Aquatic product |
| Serum | 24/285 | 7.1(1.6–31.9) |
| 25–76 | Aquatic product | PCBs | Serum | 21/293 | 1.8(0.6–5.0) | |||
| Wang2008 | Taiwan, China | Cross-sectional | 30- | Rice-bran oil men | PCBs | Serum | 155/152 | 1.7(0.7–4.6) |
| 30- | Rice-bran oil women | PCBs | Serum | 233/218 | 5.5(2.3–13.4) | |||
| Codru2007 | USA | Cross-sectional | 30- | Background | PCBs | Serum | 2.8 (0.7–10.8) | |
| 30- | Background | PCBs | Serum lipid | 2.6 (0.8–8.1) | ||||
| 30- | Background | PCB-153 | Serum | 3.0 (0.7–12.8) | ||||
| 30- | Background | PCB-153 | Serum lipid | 1.4 (0.4–4.8) | ||||
| 30- | Background |
| Serum | 2.6 (0.8–8.8) | ||||
| 30- | Background |
| Serum lipid | 2.4 (0.7–8.3) | ||||
| Rignell-Hydbom2007 | Sweden | Cross-sectional | 29–59 | Aquatic product women | PCB-153 | Serum lipid | 15/528 | 1.4(0.8–2.5) |
| 29–59 | Aquatic product women |
| Serum lipid | 15/528 | 1.3(1.1–1.5) | |||
| Cox2007 | USA | Cross-sectional | 20–74 | Background |
| Serum | 45/768 | 2.63(1.2–5.8) |
| 20–74 | Background |
| Serum lipid | 35/560 | 1.5(0.8–2.9) | |||
| Lee2006 | USA | Cross-sectional | 12- | Background | PCB-153 | Serum lipid | 52/598 | 6.8(3.0–15.5) |
| 12- | Background |
| Serum lipid | 69/704 | 4.3(1.8–10.2) | |||
| Rylander2005 | Sweden | Cross-sectional | 49–84 | Aquatic product | PCB-153 | Serum lipid | 22/358 | 1.16(1.03–1.32) |
| 49–84 | Aquatic product |
| Serum lipid | 22/358 | 1.05(1.01–1.09) | |||
| Fierens2003 | Belgium | Case-control | 50.3–59.4 | Background | PCBs | Serum lipid | 9/248 | 7.6(1.58–36.3) |
Different models adjusted by confounding, such as sex, age, BMI, total cholesterol and triglycerides, and various compounds.
stratified by BMI.
stratified by the years diagnosed after the baseline investigation.
Figure 2Subgroup analysis forest plots of the studies on T2DM risk from exposure to all three biomarkers.
(A) Result of exposure to PCB-153. (B) Result of exposure to PCBs. (C) Result of exposure to p,p′-DDE.
Subgroup analysis of the included epidemiological studies.
| Subgroup | NO. of studies | Weight | Summary OR (95%CI) | Q test (p) |
|
| PCB-153 | |||||
| Background exposure | 10 | 76.6% | 1.57(1.13–2.19) | 0.0004 | 65% |
| Specific exposure | 3 | 23.4% | - | 0.05 | 66% |
| Total | 13 | 100% | 1.52(1.19–1.94) | 0.0002 | 64% |
| Perspective study | 4 | 23.5% | 1.05(0.78–1.40) | 0.60 | 0% |
| Cross-sectional study | 9 | 76.5% | 1.69(1.24–2.31) | <0.0001 | 72% |
| Total | 13 | 100% | 1.50(1.18–1.92) | 0.0002 | 63% |
| General population | 10 | 74.7% | 1.69(1.23–2.33) | <0.0001 | 71% |
| Women | 3 | 25.3% | 1.11(0.85–1.46) | 0.41 | 0% |
| Total | 13 | 100% | 1.52(1.19–1.94) | 0.0002 | 64% |
| Serum | 6 | 38.8% | 1.36(0.95–1.95) | 0.002 | 74% |
| Serum lipid | 10 | 61.2% | 1.62(1.18–2.24) | 0.0002 | 67% |
| Total | 13 | 100% | 1.44(1.18–1.76) | <0.00001 | 74% |
| PCBs | |||||
| Background exposure | 4 | 31.6% | 1.74(1.22–2.48) | 0.22 | 30% |
| Specific exposure | 7 | 68.4% | 2.39(1.52–3.77) | 0.001 | 67% |
| Total | 11 | 100% | 2.14(1.53–2.99) | 0.002 | 59% |
| Case-control study | 2 | 10.9% | 2.83(1.18–6.81) | 0.14 | 55% |
| Cross-sectional study | 8 | 89.1% | 2.28(1.55–3.34) | 0.001 | 66% |
| Total | 10 | 100% | 2.36(1.64–3.41) | 0.0008 | 64% |
| General population | 9 | 80.4% | 2.18(1.50–3.16) | 0.006 | 59% |
| Women | 2 | 19.6% | 1.88(0.56–6.26) | 0.02 | 74% |
| Total | 11 | 100% | 2.19(1.54–3.13) | 0.001 | 62% |
| Serum | 6 | 48.3% | 2.31(1.71–3.11) | 0.36 | 8% |
| Serum lipid | 7 | 51.7% | 1.91(1.20–3.04) | 0.009 | 62% |
| Total | 11 | 100% | 2.24(1.62–3.10) | 0.001 | 58% |
| p,p′-DDE | |||||
| Background exposure | 12 | 45.2% | 1.39(1.16–1.67) | 0.18 | 25% |
| Specific exposure | 6 | 54.8% | 1.20(1.01–1.43) | 0.001 | 75% |
| Total | 18 | 100% | 1.33(1.15–1.54) | 0.0007 | 56% |
| Perspective study | 4 | 14.7% | 1.16(0.87–1.55) | 0.64 | 0% |
| Cross-sectional study | 13 | 85.3% | 1.33(1.13–1.56) | 0.0006 | 62% |
| Total | 17 | 100% | 1.29(1.12–1.48) | 0.003 | 52% |
| General population | 15 | 72.9% | 1.41(1.17–1.71) | 0.0008 | 59% |
| Women | 3 | 27.1% | 1.27(1.10–1.46) | 0.79 | 0% |
| Total | 18 | 100% | 1.33(1.15–1.54) | 0.0007 | 56% |
| Serum | 8 | 24.4% | 2.22(1.32–3.73) | 0.005 | 66% |
| Serum lipid | 14 | 75.6% | 1.34(1.14–1.57) | 0.001 | 58% |
| Total | 18 | 100% | 1.45(1.24–1.70) | <0.0001 | 62% |
Based on fixed model, others based on random model.
Figure 3A funnel plot of SE versus ln(OR) for the meta-analyses.
(A) Funnel plot for the meta-analysis on T2DM from background exposure to PCB-153. (B) Funnel plot for the subgroup analysis of serum lipid on T2DM from exposure to PCB-153. (C) Funnel plot for the subgroup analysis on T2DM from background exposure to p,p′-DDE. (D) Funnel plot for the subgroup analysis of the cross-sectional study on T2DM from exposure to p,p′-DDE. (E) Funnel plot for the subgroup analysis of the general population on T2DM from exposure to p,p′-DDE. (F) Funnel plot for the subgroup analysis of serum lipid on T2DM from exposure to p,p′-DDE.